🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Recruitingn/aAges 18 Years - anyAllAbbVie
NCT06830759 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regul

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL). * Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country. * The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study. Exclusion Criteria: * Any condition included in the contraindications section of the approved local epcoritamab label in the participating country. * Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.
💊

What it tests

  • Not listed
📍

Where

73 sites
Hospital Britanico de Buenos Aires /ID# 274419
Ciudad Autonoma de Buenos Aire, Argentina
Hospital Universitario Austral /ID# 274393
Pilar, Argentina
Instituto Alexander Fleming /ID# 277284
Ciudad Autonoma de Buenos Aire, Argentina
Hospital Privado Universitario De Córdoba /ID# 274457
Córdoba, Argentina
Hospital Italiano de Buenos Aires /ID# 274418
Buenos Aires, Argentina
Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390
Buenos Aires, Argentina
Nepean Cancer Centre, Nepean Hospital /ID# 277782
Kingswood, Australia
Calvary Mater Newcastle /ID# 277783
Waratah, Australia

…and 65 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy